Allurion Technologies, Inc. Common Stock (ALUR)
Frequently Asked Questions About Allurion Technologies, Inc. Common Stock (ALUR)
How can investors stay updated about Allurion Technologies, Inc.?
Investors can stay updated about Allurion Technologies, Inc. by following company announcements through its investor relations website, earning reports, press releases, and participating in quarterly earnings calls. Additionally, joining mailing lists or monitoring financial news platforms can provide timely information regarding the company's performance and strategic direction.
How does Allurion gather customer feedback?
Allurion Technologies, Inc. actively gathers customer feedback through user surveys, focus groups, and direct communication with healthcare providers. This information is crucial for understanding patient experiences, improving product offerings, and enhancing the overall effectiveness of the Allurion program.
How long does the Allurion Balloon stay in the stomach?
The Allurion Balloon is designed to remain in the stomach for approximately 16 weeks. During this period, it aids in weight loss by promoting early satiety and reducing overall food intake, helping patients achieve their weight loss goals before it naturally deflates and passes through the digestive system.
Is the Allurion Balloon FDA-approved?
Yes, the Allurion Balloon has received FDA approval, making it a certified option for individuals looking for non-surgical weight loss solutions. The approval is a significant milestone that validates the safety and efficacy of the product for use in the United States.
What are the benefits of the Allurion Balloon compared to traditional weight loss methods?
The Allurion Balloon offers several benefits over traditional weight loss methods, such as its non-surgical nature, quick deployment, and minimal required downtime. Additionally, it creates a feeling of fullness without requiring hospitalization or invasive interventions, making it an attractive option for many patients.
What are the key features of the Allurion Program?
The Allurion Program includes the Allurion Balloon, a comprehensive digital health platform, and ongoing support from healthcare professionals. Key features include personalized coaching, progress tracking, and access to educational resources that enhance the patient's weight loss journey and increase accountability.
What are the potential risks for investors in Allurion Technologies, Inc.?
Potential risks for investors in Allurion Technologies, Inc. include market competition, regulatory challenges, and the inherent uncertainties in the medical device industry. Factors such as product adoption rates, changes in healthcare policies, and broader economic conditions can also impact the company's performance and stock value.
What distinguishes Allurion from its competitors?
Allurion Technologies, Inc. distinguishes itself from competitors through its innovative non-surgical approach to weight loss. The Allurion Balloon's unique swallowable design, combined with a robust support program, sets it apart in a crowded market of weight management solutions, focusing on patient accessibility and outcomes.
What does Allurion Technologies, Inc. do?
Allurion Technologies, Inc. is a medical device company focused on transforming the treatment of obesity. It developed the Allurion Balloon, a non-surgical gastric balloon designed to help patients lose weight. This innovative system is intended for individuals who are overweight or obese and have struggled with traditional weight loss methods.
What is Allurion’s vision for the future?
Allurion Technologies, Inc.'s vision for the future is to be a leader in innovative, non-surgical obesity treatments worldwide, with a commitment to enhancing patient lives through effective weight management solutions. The company aims to continuously refine its offerings, expand its market presence, and embrace advancements in technology to support global health initiatives.
What is the Allurion Balloon?
The Allurion Balloon is a swallowable gastric balloon designed to assist patients in achieving sustainable weight loss. Unlike traditional gastric balloons, it is placed non-surgically through ingestion and expands in the stomach, creating a feeling of fullness to help reduce food intake without requiring invasive procedures.
What is the company’s mission?
Allurion Technologies, Inc.'s mission is to help transform patient lives by making weight loss accessible to those who need it most. The company strives to provide innovative solutions that empower patients to take control of their health and achieve lasting weight management in a safe, effective, and approachable manner.
What is the revenue model for Allurion Technologies, Inc.?
Allurion Technologies, Inc. primarily generates revenue through the sale of its Allurion Balloon and related support services. The company leverages partnerships with healthcare providers and institutions to drive adoption and facilitate widespread access to its weight loss solutions.
What is the role of technology in Allurion’s offerings?
Technology plays a central role in Allurion's offerings, particularly through its digital health platform, which integrates with the Allurion Balloon to provide real-time tracking, personalized recommendations, and virtual support. This tech-driven approach enhances patient engagement and helps optimize weight loss outcomes.
What kind of support does Allurion provide to patients?
Allurion provides comprehensive support to patients through its Allurion Program, which includes access to a digital health platform, personalized coaching, and educational resources. These tools are designed to facilitate ongoing engagement and adherence to weight loss efforts, ensuring patients receive guidance throughout their journey.
What markets does Allurion Technologies, Inc. serve?
Allurion Technologies, Inc. serves a global market, with a presence in North America, Europe, Asia, and other regions. The company has expanded its distribution networks and partnerships to bring its innovative weight loss solutions to diverse patient populations worldwide.
When did Allurion Technologies, Inc. go public?
Allurion Technologies, Inc. went public on the New York Stock Exchange (NYSE) in a transaction that was completed in 2021 through a merger with a special purpose acquisition company (SPAC). This transition to a publicly traded company was aimed at raising capital to support its growth initiatives and expand market reach.
Where is Allurion Technologies, Inc. headquartered?
Allurion Technologies, Inc. is headquartered in Natick, Massachusetts, USA. The company's location places it within a vibrant ecosystem of innovation in the biotechnology and medical device sectors, allowing it to leverage local talent and resources.
Who are the target customers of Allurion Technologies, Inc.?
The primary target customers of Allurion Technologies, Inc. include healthcare providers and specialists who treat obesity, as well as patients seeking effective non-surgical solutions for weight management. The company aims to cater to a wide demographic of individuals struggling with weight-related health issues.
What is the current price of Allurion Technologies, Inc. Common Stock?
The current price of Allurion Technologies, Inc. Common Stock is 2.900
When was Allurion Technologies, Inc. Common Stock last traded?
The last trade of Allurion Technologies, Inc. Common Stock was at 7:00 pm EDT on April 4th, 2025